公开(公告)号：US12024563B2

公开(公告)日：2024-07-02

申请号：US17505124

申请日：2021-10-19

Applicant: Acceleron Pharma Inc.

Inventor： John Knopf ,  Ravindra Kumar ,  Asya Grinberg ,  Robert Scott Pearsall ,  Dianne S. Sako ,  Roselyne Castonguay ,  Gang Li ,  Yossi Dagon

IPC: A61K38/17 ,  C07K14/71 ,  C07K16/28 ,  C12N9/12

CPC classification number: C07K16/2863 ,  A61K38/1709 ,  A61K38/177 ,  C07K14/71 ,  C12N9/1205 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/10 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

公开(公告)号：US10889626B2

公开(公告)日：2021-01-12

申请号：US16795015

申请日：2020-02-19

Applicant: Acceleron Pharma Inc.

Inventor： Jasbir Seehra ,  Robert Scott Pearsall ,  Ravindra Kumar

IPC: A61K38/00 ,  C07K14/495 ,  C07K14/475 ,  A61K38/17 ,  A61K38/19 ,  A61K31/454 ,  A61K31/7068 ,  A61K45/06 ,  C07K14/71 ,  A61K38/18 ,  A61K39/395 ,  A61K31/00 ,  C07K14/505

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

公开(公告)号：US10829533B2

公开(公告)日：2020-11-10

申请号：US16795026

申请日：2020-02-19

Applicant: Acceleron Pharma Inc.

Inventor： Jasbir Seehra ,  Robert Scott Pearsall ,  Ravindra Kumar

IPC: C07K14/495 ,  C07K14/475 ,  A61K38/17 ,  A61K38/19 ,  A61K31/454 ,  A61K31/7068 ,  A61K45/06 ,  C07K14/71 ,  A61K38/18 ,  A61K39/395 ,  A61K31/00 ,  C07K14/505

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

公开(公告)号：US20200306340A1

公开(公告)日：2020-10-01

申请号：US16482869

申请日：2018-01-31

Applicant: Acceleron Pharma Inc.

Inventor： Robert Scott Pearsall ,  Ravindra Kumar

IPC: A61K38/17 ,  A61K39/395 ,  A61P35/00

Abstract: Disclosed herein are TGFβ and ActRII antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients.

公开(公告)号：US20170306027A1

公开(公告)日：2017-10-26

申请号：US15480726

申请日：2017-04-06

Applicant: Acceleron Pharma Inc.

Inventor： John Knopf ,  Ravindra Kumar ,  Asya Grinberg ,  Robert Scott Pearsall ,  Dianne S. Sako ,  Roselyne Castonguay ,  Gang Li ,  Yossi Dagon

IPC: C07K16/28 ,  C07K14/71

CPC classification number: C07K16/2863 ,  A61K38/1709 ,  A61K38/177 ,  C07K14/71 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/10 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74 ,  C12N9/1205

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

公开(公告)号：US20170204382A1

公开(公告)日：2017-07-20

申请号：US15336363

申请日：2016-10-27

Applicant: Acceleron Pharma Inc.

Inventor： Jasbir Seehra ,  Robert Scott Pearsall ,  Ravindra Kumar

IPC: C12N9/12 ,  C12Q1/68

CPC classification number: C12N9/12 ,  A61K38/179 ,  A61K38/1796 ,  C07K14/47 ,  C07K14/475 ,  C07K2319/30 ,  C12Q1/6897 ,  C12Y207/1103

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

公开(公告)号：US12258380B2

公开(公告)日：2025-03-25

申请号：US17666705

申请日：2022-02-08

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/705 ,  C07K14/71

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.

公开(公告)号：US20240158468A1

公开(公告)日：2024-05-16

申请号：US18236082

申请日：2023-08-21

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/71 ,  A61K38/45 ,  C12N9/12

CPC classification number: C07K14/71 ,  A61K38/45 ,  C12N9/12 ,  C12Y207/1103 ,  A61K38/00 ,  C07K2319/30

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

公开(公告)号：US20220396607A1

公开(公告)日：2022-12-15

申请号：US16951192

申请日：2020-11-18

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne Sako ,  Robert Scott Pearsall ,  Roselyne Castonguay

IPC: C07K14/71 ,  A61K38/45 ,  C12N9/12

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.

公开(公告)号：US20220289852A1

公开(公告)日：2022-09-15

申请号：US17505124

申请日：2021-10-19

Applicant: Acceleron Pharma Inc.

Inventor： John Knopf ,  Ravindra Kumar ,  Asya Grinberg ,  Robert Scott Pearsall ,  Dianne S. Sako ,  Roselyne Castonguay ,  Gang Li ,  Yossi Dagon

IPC: C07K16/28 ,  C12N9/12 ,  A61K38/17 ,  C07K14/71

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.